Loading...
•
Mar 31, 2024
ResMed Q3 2024 Earnings Report
ResMed's Q3 2024 results reflected strong demand and operational efficiencies, leading to increased profitability.
Key Takeaways
ResMed reported a 7% increase in revenue to $1.2 billion, a 25% increase in operating profit, and a 29% increase in net income. Diluted earnings per share were $2.04, and non-GAAP diluted earnings per share were $2.13.
Revenue increased by 7% year-over-year to $1.2 billion.
Gross margin grew 260 bps to 57.9%.
Income from operations increased 25%.
Diluted earnings per share reached $2.04; non-GAAP diluted earnings per share was $2.13.
ResMed
ResMed
ResMed Revenue by Segment
ResMed Revenue by Geographic Location
Revenue by Segment
Total Devices Revenue
CapyFin.comTotal Masks and other Revenue
CapyFin.comRevenue by Geographic Location
U.S., Canada, and Latin America Revenue
CapyFin.comEurope, Asia, and other markets Revenue
CapyFin.com Forward Guidance
The document does not contain explicit forward guidance. Therefore, a summary and related bullet points cannot be provided.
Revenue & Expenses
Visualization of income flow from segment revenue to net income